A Korea University research team has discovered that pitavastatin, a widely used lipid-lowering drug, can directly inhibit the Mcl-1 protein—an essential survival factor for therapy-resistant ...

Triple-negative breast cancer (TNBC) is among the most aggressive types of breast cancer, lacking estrogen, progesterone, and HER2 receptors and thus ...

Exelixis, Inc. and Natera , a global leader in cell-free DNA and precision medicine, today announced their collaboration on the planned Exelixis-sponsored STELLAR-316 trial. This randomized phase 3 ...

Cancer researchers have long treated genetic chaos and epigenetic rewiring as separate engines of disease, two parallel ...

We are thrilled to welcome Arjun and Cyndi to the Compass team. They are highly accomplished leaders with decades of commercial and clinical development experience,” said Thomas Schuetz, MD, PhD, CEO ...

Compass Therapeutics ( ($CMPX) ) has issued an update. On January 6, 2026, Compass Therapeutics reported an estimated, unaudited cash and ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; ...

Hong Kong, Shanghai Tuesday, January 6, 2026, 13:00 Hrs [IST] ...

Summit Therapeutics Inc. ("Summit," "we," or the "Company") today announced that it will participate in and present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California, ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces that it has initiated the Phase III ...

Global cancer cases have surged dramatically, doubling since 1990 and reaching 18.5 million new diagnoses in 2023. Deaths ...

Studies published in Nature Cancer reveal how bacterial presence in head and neck cancers affects treatment response, ...